Your shopping cart is currently empty

Milademetan (DS-3032) is an orally active and potent MDM2 inhibitor with antitumor activity that induces G1 cell cycle arrest, senescence, and apoptosis.Milademetan is used in the study of acute myeloid leukemia and solid tumors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $89 | In Stock | - | |
| 5 mg | $179 | In Stock | - | |
| 10 mg | $289 | In Stock | - | |
| 25 mg | $546 | In Stock | - | |
| 50 mg | $892 | In Stock | - | |
| 100 mg | $1,530 | In Stock | - | |
| 1 mL x 10 mM (in DMSO) | $246 | In Stock | In Stock |
| Description | Milademetan (DS-3032) is an orally active and potent MDM2 inhibitor with antitumor activity that induces G1 cell cycle arrest, senescence, and apoptosis.Milademetan is used in the study of acute myeloid leukemia and solid tumors. |
| In vitro | Milademetan (DS-3032) selectively induces CDKNA1, BAX, and MDM2 expression and stabilizes TP53 in neuroblastoma cells with wild-type TP53[3]. Treatment with Milademetan (DS-3032) enhances TP53 target gene expression, leading to G1 cell cycle arrest, senescence, and apoptosis[3]. In neuroblastoma cells with wild-type TP53, independent of MYCN status, Milademetan (DS-3032, 0-2000 nM) treatment selectively inhibits viability, proliferation, and migration[2]. |
| In vivo | In mice xenografted with neuroblastoma cells possessing functional TP53, oral gavage administration of Milademetan (DS-3032) at a dose of 50 mg/kg delays tumor growth and improves overall survival[2]. |
| Synonyms | RAIN-32, DS3032b, DS-3032 |
| Molecular Weight | 618.53 |
| Formula | C30H34Cl2FN5O4 |
| Cas No. | 1398568-47-2 |
| Smiles | CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (88.92 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.62 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.